electroCore

The page explains how vagus nerve stimulation offers a non-pharmacological, non-invasive treatment for PTSD symptoms.

The page details electroCore’s pipeline of nVNS therapies in development for neurology and metabolic disorders.

The company develops non-invasive vagus nerve stimulation (nVNS) technology to treat challenging diseases.

Non-invasive vagus nerve stimulation (nVNS) delivers a proprietary signal through the skin to either the right or the left branches of the vagus nerve in the neck.

The page lists publications on non-invasive vagus nerve stimulation (nVNS) and its effects on patient outcomes across medical conditions.

Desitin will distribute electroCore’s gammaCore device in Germany for migraine and cluster headache treatment, leveraging its CNS salesforce.

The VNS-REHAB study in *The Lancet* shows vagus nerve stimulation (VNS) during rehabilitation improves arm function after ischemic stroke.

electroCore honors National Military Appreciation Month by supporting healthcare solutions for veterans.

The page describes career opportunities and benefits at electroCore, a bioelectronic technology company.

The company helps patients globally access non-invasive vagus nerve stimulation (nVNS).

Carbon Reduction Plan - electroCore UK Ltd is committed to achieving Net Zero emissions by 2050.

The page shows a visual timeline of electroCore and non-invasive vagus nerve stimulation (nVNS) innovations.

The page provides contact details for electroCore’s Investors, Media, Business Development, Clinical Trials, and Product Feedback inquiries.

electroCore develops non-invasive vagus nerve stimulation (nVNS) therapy for neurology and metabolic disorders.

Terms and Conditions apply to the purchase of TAC-STIM Products from electroCore under the TAC-STIM Order Form or Quote Form signed by the Customer and electroCore

Terms and Conditions for the usage of gammaCore

electroCore submits a 510(k) Premarket Notification to the FDA for its Quell® device, targeting chronic chemotherapy-induced peripheral neuropathy (CIPN). The submission includes clinical data from two studies involving 168 participants, showing improvements in quality of life and a roughly 40% reduction in neuropathic pain scores for the treatment group.

Oct 2026electroCoreNews article

ElectroCore’s transcutaneous cervical vagus nerve stimulation (tcVNS) shows potential to accelerate neural processes in visual skill learning. An fMRI study involving 50 healthy adults indicates improved executive efficiency and stronger behavioral coordination. The findings suggest tcVNS may enhance cognitive performance during skill acquisition.

Oct 2026electroCoreNews article

ElectroCore, Inc. names **Joshua Lev** and **Mike Fox** as its new **co-chief executive officers**, combining their leadership to advance the company’s bioelectronic medicine and wellness initiatives. The appointment underscores internal confidence in their complementary expertise to drive shareholder value. ElectroCore specializes in commercial-stage therapies targeting metabolic and inflammatory conditions.

Sep 2026electroCoreNews article

electroCore reports **$9.5 million in net sales for Q2 2026**, marking a **28% year-over-year increase** from $7.4 million in Q2 2025. The company’s net loss narrows to **$3.1 million**, a **17% reduction** from the prior-year period, while adjusted EBITDA loss improves by **26%**. electroCore also raises its **2026 revenue guidance to exceed 30% growth**.

Aug 2026electroCoreNews article